Personalised Medicine

Precise diagnosis, more effective treatment and fewer side effects for the patients – that is the purpose of personalised medicine. The field aims to improve diagnosis and tailor treatment to the individual patient’s biological and clinical profile. All supported by the momentous development in genomic technologies and insights.

What We Do

We work in a range of overlapping areas, including genomics, other ‘omics, pharmacology, medical bioinformatics, molecular biology, imaging, and gene therapy. In a translational framework - from lab bench to bedside and vice versa - we study huge data sets in clinical and population based cohorts as well as cell and animal models.

Who We Are

We are more than 23 groups and 70 staff members with diverse expertise in personalised medicine.

Meet Associate Professor
Jane Hvarregaard Christensen

Portrait of Jane Hvarregaard Christensen

Understanding the molecular processes ensuring that our brain is fit and healthy. This is the overarching aim for associate professor Jane Hvarregaard Christensen.

Meet Professor
Ulf Simonsen

Meet Ulf Simonsen

To understand, invent or improve drugs, so that we get better medicines tomorrow. This is the main purpose of professor Ulf Simonsen’s life in pharmacology.

Meet Anders Børglum,
Research Theme Coordinator

Research Theme Contact

Meet all of us


Events


Research Centres


Research Centre iPSYCH, Photo: Colourbox

The purpose of iPSYCH is to find the causes and create the basis for better treatment and prevention of five of the most serious mental illnesses; autism, ADHD, schizophrenia, bipolar disorder and depression.


Research Centre iSEQ, Photo: Colourbox

The overall aim of iSEQ is to integrate multi-layered biological sequencing data with comprehensive phenotypic and environmental data to increase the understanding of the complex molecular systems governing biological function and human disease.


Read more about PASCAL-MID

The main aim of PASCAL-MID is to establish genetic therapies for monogenic diseases based on implementation of the CRISPR technology in hematopoietic stem cells. Focusing on immunodeficiencies, we aim at founding the technologies and infrastructure for future treatment.

DNA strings, Photo: Colourbox